If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 8 of 8
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
Objective
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Protocol No
GOG-3082-ACRIVON-ACR-368-201
Categories
A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE
Objective
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)
Protocol No
ANTHOS-ANT-007
Categories
Cancer,
Eye/Orbital Cancers,
Skin Cancers,
Cervix,
Lip, Oral Cavity and Pharynx,
Sarcoma,
Other Gastrointestinal,
Other Blood Related,
Pancreas/Liver,
Uterine,
Other Respiratory,
Gynecologic Cancers,
Brain and Spine Cancers,
Bladder,
Lung,
Head and Neck Cancers,
Leukemia,
Prostate,
Esophagus,
Thoracic Cancers,
Colorectal,
Hematologic/Blood Related Cancers,
Gastrointestinal Cancers,
Kidney,
Endocrine Cancers,
Prostate and Urologic Cancers,
Multiple Myeloma,
Breast Cancers
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Objective
To compare the non-inferiority of bilateral salpingectomy (BLS) with delayed oophorectomy to bilateral salpingo-oophorectomy (BSO) to reduce the risk of ovarian cancer among women with deleterious BRCA1 germline mutations.
Protocol No
NRG-CC008
Categories
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Objective
Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Protocol No
NRG-GY022
Categories
A Phase IB and Randomized Phase II Trial of Megestrol Acetate with or without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer
Objective
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your endometrial cancer. The usual approach is defined as care most people get for endometrial cancer.
Protocol No
NRG-GY028
Categories
REMASTer: REcurrent Brain Metastases After SRS Trial
Objective
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Protocol No
MONTERIS-CL10153-REMASTER
Categories
Cancer,
Endocrine Cancers,
Uterine,
Other Urologic,
Colorectal,
Cervix,
Lung,
Brain and Spine Cancers,
Prostate,
Stomach,
Skin Cancers,
Prostate and Urologic Cancers,
Other Respiratory,
Gastrointestinal Cancers,
Breast Cancers,
Head and Neck Cancers,
Esophagus,
Ovary,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Gynecologic Cancers,
Sarcoma,
Eye/Orbital Cancers
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Objective
Phase 1/2, Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Protocol No
TAKEDA-TAK-280-1501
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
Objective
Olanzapine vs Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Protocol No
ALLIANCE-A222004-ANOREXIA
Categories
Cancer,
Cervix,
Lip, Oral Cavity and Pharynx,
Endocrine Cancers,
Prostate and Urologic Cancers,
Other Skin,
Breast Cancers,
Other Respiratory,
Gastrointestinal Cancers,
Uterine,
Thoracic Cancers,
Gynecologic Cancers,
Sarcoma,
Eye/Orbital Cancers,
Skin Cancers,
Larynx,
Head and Neck Cancers,
Brain and Spine Cancers